Aerobic, Strength, Kegel (ASK) Exercise Intervention Perceptions for Postpartum Health (ASK)
2026年9月1日 更新者：LAI KWAN LAM、Chinese University of Hong Kong
Aerobic, Strength, Kegel (ASK) Exercise Intervention Perceptions for Postpartum Health: a Pilot Randomized Controlled Trial
The goal of this pilot clinical trial is to learn whether a 12-week home-based exercise programme is feasible, acceptable, and safe for postpartum women in Hong Kong who had hypertensive disorders of pregnancy. The exercise programme is called the Aerobic, Strength, and Kegel exercise programme, or ASK programme.
The main questions this study aims to answer are:
- Can postpartum women follow the ASK exercise programme at home?
- Is the ASK exercise programme acceptable and safe?
- Does the ASK exercise programme show early benefits for postpartum recovery and health?
Researchers will compare women who receive the ASK exercise programme with women who receive standard postnatal care.
Participants will be randomly assigned to one of the two groups. They will complete study assessments at the beginning of the study and after 12 weeks. Women in the ASK exercise programme group will complete three 60-minute exercise sessions per week for 12 weeks, supported by a mobile app and wearable device. Women in the standard postnatal care group will continue to receive usual postnatal care.
調査の概要
詳細な説明
This is a parallel-group pilot randomized controlled trial designed to evaluate the feasibility, acceptability, safety, and preliminary effectiveness of the ASK Programme, a 12-week home-based postpartum exercise intervention for Asian women in Hong Kong. The ASK Programme combines aerobic training, strength training, and Kegel-based pelvic floor muscle training, and is delivered through a study app with wearable-supported monitoring.
Eligible participants will be enrolled at 6 to 8 weeks postpartum and randomized in a 1:1 ratio to either the ASK Programme intervention group or the standard postnatal care control group. Participants in the intervention group will complete three home-based ASK exercise sessions per week for 12 weeks. Each session will include warm-up, aerobic training, strength training, pelvic floor muscle training, and cool-down. The control group will receive standard postnatal care.
Assessments will be conducted at baseline and within 1 week after completion of the 12-week intervention. The study will collect feasibility, adherence, safety, acceptability, clinical, behavioral, psychosocial, physiological, cardiometabolic, and exploratory biological data to inform the design of a future full-scale randomized controlled trial.
研究の種類
介入
入学 (推定)
40
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：LAI KWAN LAM, PhD
- 電話番号：+85235054267
- メール：laikwanlam@cuhk.edu.hk
研究場所
-
-
Hong Kong
-
Hong Kong、Hong Kong、香港
- The Department of Obstetrics and Gynaecology, The Chinese University Of Hong Kong
-
コンタクト：
- YAO WANG, PhD
- 電話番号：+85235051289
- メール：yaowang1@cuhk.edu.hk
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Female Asian postpartum women aged 18 to 45 years
- Singleton pregnancy
- 6 to 8 weeks postpartum at the time of enrolment
- Medically stable after childbirth
- Physically able to participate in low-to-moderate intensity exercise training
- Able and willing to participate in the 12-week study programme
- Able to use the study app and wearable device, or willing to receive instruction on their use
- Able to provide written informed consent
Exclusion Criteria:
- Multiple pregnancy
- Severe postpartum medical complications or conditions contraindicating exercise participation
- Severe cardiovascular, respiratory, neurological, or major musculoskeletal conditions that may limit safe participation in exercise
- Current use of medication likely to substantially affect cardiac function, including heart failure therapy
- Antibiotic treatment within the preceding month
- Severe mental illness or other condition affecting the ability to provide informed consent or comply with study procedures
- Any medical, obstetric, or psychological condition judged by the research team or attending clinician to make participation unsafe or inappropriate
- Inability or unwillingness to adhere to the 12-week ASK programme or study assessments
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：支持療法
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：ASK Exercise Programme
Participants assigned to this arm will receive the Aerobic, Strength, and Kegel exercise programme (ASK programme) in addition to standard postnatal care.
The ASK programme is a 12-week home-based, app-guided exercise intervention supported by a wearable device.
Participants will be asked to complete three exercise sessions per week, with each session lasting approximately 60 minutes.
The programme includes aerobic exercise, strength training, and Kegel-based pelvic floor muscle training.
|
The ASK Exercise Programme is a 12-week home-based, app-guided exercise intervention supported by a wearable device.
Participants will be asked to complete three sessions per week, with each session lasting approximately 60 minutes.
The programme includes aerobic exercise, strength training, and Kegel-based pelvic floor muscle training.
The mobile app and wearable device will be used to support exercise delivery, self-monitoring, and adherence tracking.
|
|
介入なし：Standard Postnatal Care
Participants allocated to the control group will receive standard postnatal care, including routine postpartum follow-up and general health advice.
They will not receive the ASK programme during the 12-week study period.
They will complete the same baseline and post-intervention assessments as participants in the intervention group.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recruitment rate to the ASK Exercise Programme
時間枠：From recruitment initiation to 12 weeks
|
Recruitment rate will be calculated as the number of participants enrolled divided by the number of eligible participants approached.
The outcome will be reported as a percentage of eligible participants approached.
|
From recruitment initiation to 12 weeks
|
|
Retention rate in the ASK Exercise Programme
時間枠：From baseline to 12 weeks
|
Retention rate will be calculated as the number of enrolled participants who complete the 12-week follow-up assessment divided by the total number of enrolled participants.
The outcome will be reported as a percentage of enrolled participants.
|
From baseline to 12 weeks
|
|
Dropout rate from the ASK Exercise Programme
時間枠：From baseline to 12 weeks
|
Dropout rate will be calculated as the number of participants who withdraw or are lost to follow-up before the 12-week assessment divided by the total number of enrolled participants.
The outcome will be reported as a percentage of enrolled participants.
|
From baseline to 12 weeks
|
|
Assessment completion in the ASK Exercise Programme
時間枠：From baseline to 12 weeks
|
Assessment completion rate will be calculated as the number of completed planned study assessments divided by the total number of planned study assessments.
The outcome will be reported as a percentage of planned study assessments.
|
From baseline to 12 weeks
|
|
Participant satisfaction rate
時間枠：At 12 weeks
|
Participant satisfaction will be assessed using a study-specific acceptability questionnaire administered at 12 weeks.
Satisfaction will be defined as reporting "satisfied" or "very satisfied" with the ASK Exercise Programme.
The outcome will be reported as the percentage of participants who are satisfied or very satisfied.
|
At 12 weeks
|
|
ASK session completion rate
時間枠：Throughout the 12-week intervention period
|
ASK session completion rate will be calculated as the number of prescribed ASK exercise sessions completed divided by the total number of prescribed ASK exercise sessions during the 12-week intervention period.
Session completion will be assessed using app-recorded exercise completion data.
The outcome will be reported as a percentage of prescribed ASK exercise sessions.
|
Throughout the 12-week intervention period
|
|
Adverse events related to the ASK Exercise Programme
時間枠：Throughout the 12-week intervention period
|
Safety will be assessed as the number of participants who experience one or more adverse events related to the ASK Exercise Programme during the 12-week intervention period.
Adverse events and exercise-related symptoms will be collected using participant symptom reports and study adverse event records.
The outcome will be reported as the number of participants with adverse events related to the ASK Exercise Programme.
|
Throughout the 12-week intervention period
|
|
Postpartum recovery score
時間枠：Baseline and 12 weeks
|
Postpartum recovery will be assessed using the Obstetric Quality of Recovery-10.
The change from baseline to 12 weeks in the total Obstetric Quality of Recovery-10 score will be calculated.
Total scores range from 0 to 100, with higher scores indicating better postpartum recovery.
|
Baseline and 12 weeks
|
|
Postnatal depressive symptom score
時間枠：Baseline and 12 weeks
|
Postnatal depressive symptoms will be assessed using the Edinburgh Postnatal Depression Scale.
The change from baseline to 12 weeks in the total Edinburgh Postnatal Depression Scale score will be calculated.
Total scores range from 0 to 30, with higher scores indicating more severe depressive symptoms.
|
Baseline and 12 weeks
|
|
Pelvic floor symptom distress score
時間枠：Baseline and 12 weeks
|
Pelvic floor symptom distress will be assessed using the Pelvic Floor Distress Inventory-20.
The change from baseline to 12 weeks in the total Pelvic Floor Distress Inventory-20 score will be calculated.
Total scores range from 0 to 300, with higher scores indicating greater pelvic floor symptom distress.
|
Baseline and 12 weeks
|
|
Sleep quality score
時間枠：Baseline and 12 weeks
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index.
The change from baseline to 12 weeks in the global Pittsburgh Sleep Quality Index score will be calculated.
Global scores range from 0 to 21, with higher scores indicating poorer sleep quality.
|
Baseline and 12 weeks
|
|
Breastfeeding self-efficacy score
時間枠：Baseline and 12 weeks
|
Breastfeeding self-efficacy will be assessed using the Breastfeeding Self-Efficacy Scale-Short Form.
The change from baseline to 12 weeks in the total Breastfeeding Self-Efficacy Scale-Short Form score will be calculated.
Total scores range from 14 to 70, with higher scores indicating greater breastfeeding self-efficacy.
|
Baseline and 12 weeks
|
|
Health-related quality of life score
時間枠：Baseline and 12 weeks
|
Health-related quality of life will be assessed using the Short Form-12 Health Survey.
The change from baseline to 12 weeks in the health-related quality of life score will be calculated.
The outcome will be reported as a score on a scale, with higher scores indicating better health-related quality of life.
|
Baseline and 12 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Body mass index
時間枠：Baseline and 12 weeks
|
Body mass index will be calculated as body weight in kilograms divided by height in meters squared.
The change from baseline to 12 weeks in body mass index will be calculated.
The outcome will be reported in kg/m².
|
Baseline and 12 weeks
|
|
Waist-hip ratio
時間枠：Baseline and 12 weeks
|
Waist-hip ratio will be calculated as waist circumference divided by hip circumference.
The change from baseline to 12 weeks in waist-hip ratio will be calculated.
The outcome will be reported as a ratio.
|
Baseline and 12 weeks
|
|
Resting heart rate
時間枠：Baseline and 12 weeks
|
Resting heart rate will be measured at baseline and 12 weeks.
The change from baseline to 12 weeks in resting heart rate will be calculated.
The outcome will be reported in beats per minute.
|
Baseline and 12 weeks
|
|
Systolic blood pressure
時間枠：Baseline and 12 weeks
|
Systolic blood pressure will be measured at baseline and 12 weeks where available through home or routine clinical measurement.
The change from baseline to 12 weeks in systolic blood pressure will be calculated.
The outcome will be reported in mmHg.
|
Baseline and 12 weeks
|
|
Diastolic blood pressure
時間枠：Baseline and 12 weeks
|
Diastolic blood pressure will be measured at baseline and 12 weeks where available through home or routine clinical measurement.
The change from baseline to 12 weeks in diastolic blood pressure will be calculated.
The outcome will be reported in mmHg.
|
Baseline and 12 weeks
|
|
Fasting glucose concentration
時間枠：Baseline and 12 weeks
|
Fasting glucose concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in fasting glucose concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
HbA1c
時間枠：Baseline and 12 weeks
|
HbA1c will be measured using blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in HbA1c will be calculated.
The outcome will be reported as a percentage.
|
Baseline and 12 weeks
|
|
Triglyceride concentration
時間枠：Baseline and 12 weeks
|
Triglyceride concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in triglyceride concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
Total cholesterol concentration
時間枠：Baseline and 12 weeks
|
Total cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in total cholesterol concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
High-density lipoprotein cholesterol concentration
時間枠：Baseline and 12 weeks
|
High-density lipoprotein cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in high-density lipoprotein cholesterol concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
Low-density lipoprotein cholesterol concentration
時間枠：Baseline and 12 weeks
|
Low-density lipoprotein cholesterol concentration will be measured using fasting blood samples at baseline and 12 weeks.
The change from baseline to 12 weeks in low-density lipoprotein cholesterol concentration will be calculated.
The outcome will be reported in mmol/L.
|
Baseline and 12 weeks
|
|
Post-exercise recovery heart rate
時間枠：Baseline and 12 weeks
|
Cardiorespiratory fitness will be assessed using a 3-minute step test.
Post-exercise recovery heart rate will be recorded after completion of the test.
The change from baseline to 12 weeks in post-exercise recovery heart rate will be calculated.
The outcome will be reported in beats per minute.
|
Baseline and 12 weeks
|
|
Daily step count
時間枠：Throughout the 12-week intervention period
|
Daily step count will be recorded using wearable-derived activity data.
Mean daily step count during the 12-week intervention period will be calculated.
The outcome will be reported as steps per day.
|
Throughout the 12-week intervention period
|
|
Daily active minutes
時間枠：Throughout the 12-week intervention period
|
Daily active minutes will be recorded using wearable-derived activity data.
Mean daily active minutes during the 12-week intervention period will be calculated.
The outcome will be reported as minutes per day.
|
Throughout the 12-week intervention period
|
|
Exploratory gut microbiome profile
時間枠：Baseline and 12 weeks
|
Gut microbiome profiles will be assessed using stool samples collected at baseline and 12 weeks.
Changes from baseline to 12 weeks in gut microbiome profiles will be explored, including microbial diversity and taxonomic composition, depending on sample availability and sequencing quality.
|
Baseline and 12 weeks
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Yao Wang, PhD、Chinese University of Hong Kong
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年12月1日
一次修了 (推定)
2029年11月30日
研究の完了 (推定)
2029年11月30日
試験登録日
最初に提出
2026年7月28日
QC基準を満たした最初の提出物
2026年8月24日
最初の投稿 (実際)
2026年8月27日
学習記録の更新
投稿された最後の更新 (実際)
2026年9月3日
QC基準を満たした最後の更新が送信されました
2026年9月1日
最終確認日
2026年7月1日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- CREC Ref. No.:2026.436
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。